• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

No­vo Nordisk paus­es ad cam­paign for obe­si­ty drug We­govy amid un­prece­dent­ed de­mand

2 weeks ago
Pharma
Marketing

Vir en­lists J&J vet to run busi­ness de­vel­op­ment; Gilead finds Kite suc­ces­sor to Christi Shaw

3 weeks ago
Peer Review

Am­gen can close Hori­zon deal by Sep­tem­ber if no rul­ing from courts on FTC suit

3 weeks ago
Pharma
Law

Ex­clu­sive: Cell and gene ther­a­py biotech cre­ator Re­play plucks Al­lo­gene CMO Arun Bal­aku­maran to lead clin­i­cal tri­als

3 weeks ago
People
Cell/Gene Tx

Pri­or­i­ty re­view for Take­da’s ul­tra-rare blood clot ERT; FDA to give an­oth­er look at Arde­lyx’s CKD drug

3 weeks ago
News Briefing
FDA+

Ex-FDA neu­ro chief Bil­ly Dunn is tak­ing a spin through the re­volv­ing door with bio­phar­ma — and that's a prob­lem

3 weeks ago
Bioregnum
FDA+

Roche touts PhII win for BTK in­hibitor in mul­ti­ple scle­ro­sis as PhI­II show­down with Sanofi, Mer­ck KGaA, No­var­tis looms

3 weeks ago
R&D

BioX­cel touts healthy vol­un­teer da­ta for neu­ro ther­a­py; Io­n­is, Chi­nook part­ner on rare kid­ney dis­ease

3 weeks ago
News Briefing

$97M gene ther­a­py con­sor­tium aims to give com­pa­nies and rare dis­ease fam­i­lies a ‘north star’

3 weeks ago
R&D
FDA+

Pe­ter Hecht has a new syn­di­cate, $81M in back­ing and a fresh shot at glo­ry as his last start-up sput­ters out

3 weeks ago
R&D

Der­ma­van­t's Vta­ma works again in eczema as Roivant sub­sidiary seeks la­bel ex­pan­sion next year

3 weeks ago
R&D

Mod­er­na goes af­ter Al­ny­lam, fil­ing coun­ter­claims in Spike­vax patent suit

3 weeks ago
Pharma
Law

Still un­der clin­i­cal hold, Ful­crum locks in sea­soned com­mer­cial leader as CEO

3 weeks ago
People
R&D

Verve names sec­ond PC­SK9 can­di­date; Ex­sci­en­tia picks an­oth­er AI-cre­at­ed mol­e­cule for clin­ic

3 weeks ago
News Briefing

Fu­sion and Cyteir re­fo­cus pipelines; Nona Bio­sciences col­lab­o­rat­ing with Phar­maEssen­tia

3 weeks ago
News Briefing

Astel­las pres­i­dent jumps to a new Fron­tier; Gri­fols chair­man named CEO, break­ing fam­i­ly tra­di­tion

4 weeks ago
Peer Review

Ole­ma gives small up­date to breast can­cer drug at cen­ter of lay­offs, 2021 da­ta leak

4 weeks ago
R&D

Deer­field launch­es ra­dio­ther­a­py com­pa­ny; UCLA gene edit­ing spin­out se­cures funds

4 weeks ago
News Briefing

Ex­clu­sive: Af­ter win­ning le­gal bat­tle, for­mer Phase­Bio in­vestor finds US buy­er for its PhI­II drug to re­verse Bril­in­ta

4 weeks ago
Deals

The E100: Ex­tend­ing run­ways, dump­ing drugs, fac­tor­ing in a bank­ing cri­sis and grap­pling with the IRA — there's a lot for biotech ex­ecs to deal with

4 weeks ago
Bioregnum
Special

FDA ad­comm votes unan­i­mous­ly in fa­vor of ben­e­fit-risk pro­file of over-the-counter con­tra­cep­tive Opill

4 weeks ago
Pharma

CRO deal space con­tin­ues to buzz as Gen­e­sis Drug Dis­cov­ery buys JSS Med­ical Re­search

4 weeks ago
Deals
Outsourcing

Chiesi, Pro­tal­ix's Fab­ry dis­ease treat­ment is ap­proved as Elfab­rio joins Fab­razyme, Galafold

4 weeks ago
FDA+

FDA lifts par­tial hold on Salarius' Ew­ing sar­co­ma drug tri­al

4 weeks ago
R&D
FDA+
First page Previous page 12345 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2023

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET